IHH Healthcare expands cancer treatment with new radiotherapy investment

It delivers radiation 400 times faster than existing methods.

IHH Healthcare has invested in US-based medical technology company TibaRay to support the development and deployment of next-generation radiation therapy systems for cancer treatment.

The investment supports IHH’s transformation agenda and its Centres of Excellence strategy in oncology, cardiology and orthopaedics, as the Group looks to scale new technologies across its hospital network.

TibaRay is developing proprietary linear accelerators designed to deliver radiation at ultra-high speeds — more than 400 times faster than current systems — while maintaining high precision. The technology aims to shorten treatment times, improve dose control and reduce radiation exposure to healthy tissue.

The systems are based on research and patents from institutions including Stanford University, SLAC National Accelerator Laboratory, and Arizona State University.

TibaRay Chief Executive Officer Thinh Tran said the partnership comes as the company prepares to launch Galactica, its first commercial system.

Under the collaboration, IHH and TibaRay will work on clinical evaluations, knowledge sharing and future deployment of the technology across IHH’s network in key markets.